232 related articles for article (PubMed ID: 38098449)
1. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Wu Y; Chen S; Yang X; Sato K; Lal P; Wang Y; Shinkle AT; Wendl MC; Primeau TM; Zhao Y; Gould A; Sun H; Mudd JL; Hoog J; Mashl RJ; Wyczalkowski MA; Mo CK; Liu R; Herndon JM; Davies SR; Liu D; Ding X; Evrard YA; Welm BE; Lum D; Koh MY; Welm AL; Chuang JH; Moscow JA; Meric-Bernstam F; Govindan R; Li S; Hsieh J; Fields RC; Lim KH; Ma CX; Zhang H; Ding L; Chen F
Cancer Res; 2023 Dec; 83(24):4161-4178. PubMed ID: 38098449
[TBL] [Abstract][Full Text] [Related]
2. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
3. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
4. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Albiges L; McGregor BA; Heng DYC; Procopio G; de Velasco G; Taguieva-Pioger N; Martín-Couce L; Tannir NM; Powles T
Cancer Treat Rev; 2024 Jan; 122():102652. PubMed ID: 37980876
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
8. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.
Park KY; Hefti HO; Liu P; Lugo-Cintrón KM; Kerr SC; Beebe DJ
Integr Biol (Camb); 2021 Dec; 13(11):259-268. PubMed ID: 34931665
[TBL] [Abstract][Full Text] [Related]
9. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G; Claps M; Pircher C; Porcu L; Sepe P; Guadalupi V; De Giorgi U; Bimbatti D; Nolè F; Carrozza F; Buti S; Iacovelli R; Ciccarese C; Masini C; Baldessari C; Doni L; Cusmai A; Gernone A; Scagliarini S; Pignata S; de Braud F; Verzoni E
Tumori; 2023 Feb; 109(1):129-137. PubMed ID: 36447337
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
12. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Tannir NM; Schwab G; Grünwald V
Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
Desai A; Small EJ
Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
18. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
19. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
[TBL] [Abstract][Full Text] [Related]
20. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
